User login
Key clinical point: In patients with metastatic breast cancer (BC), germline BRCA1/2 mutation (gBRCAm) had a differential prognostic impact for triple-negative BC (TNBC) or hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) BC.
Major finding: Compared with gBRCA wild-type (WT) BC, gBRCAm BC showed comparable overall survival (OS) and first-line progression-free survival (PFS1) outcomes in the overall cohort of patients with metastatic BC (both P > .05), better OS (hazard ratio [HR] 0.76; P = .027) and PFS1 (HR 0.69; P = .001) in the TNBC subgroup, and worse PFS1 (HR 1.23; P = .024) in the HR+/HER2− BC subgroup.
Study details: Findings are from a retrospective cohort including 20,624 patients with newly diagnosed metastatic BC, of which 325 had gBRCAm, 1138 had gBRCA WT, and 19,161 had not tested for gBRCA.
Disclosures: This study was funded by an industrial consortium. Several authors declared receiving personal fees, grants, nonfinancial support, or travel support from several sources, including some of the companies in the consortium. Seventeen authors declared no conflicts of interest.
Source: Mailliez A et al. Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database. Int J Cancer. 2022 (Sep 26). Doi: 10.1002/ijc.34304
Key clinical point: In patients with metastatic breast cancer (BC), germline BRCA1/2 mutation (gBRCAm) had a differential prognostic impact for triple-negative BC (TNBC) or hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) BC.
Major finding: Compared with gBRCA wild-type (WT) BC, gBRCAm BC showed comparable overall survival (OS) and first-line progression-free survival (PFS1) outcomes in the overall cohort of patients with metastatic BC (both P > .05), better OS (hazard ratio [HR] 0.76; P = .027) and PFS1 (HR 0.69; P = .001) in the TNBC subgroup, and worse PFS1 (HR 1.23; P = .024) in the HR+/HER2− BC subgroup.
Study details: Findings are from a retrospective cohort including 20,624 patients with newly diagnosed metastatic BC, of which 325 had gBRCAm, 1138 had gBRCA WT, and 19,161 had not tested for gBRCA.
Disclosures: This study was funded by an industrial consortium. Several authors declared receiving personal fees, grants, nonfinancial support, or travel support from several sources, including some of the companies in the consortium. Seventeen authors declared no conflicts of interest.
Source: Mailliez A et al. Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database. Int J Cancer. 2022 (Sep 26). Doi: 10.1002/ijc.34304
Key clinical point: In patients with metastatic breast cancer (BC), germline BRCA1/2 mutation (gBRCAm) had a differential prognostic impact for triple-negative BC (TNBC) or hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2−) BC.
Major finding: Compared with gBRCA wild-type (WT) BC, gBRCAm BC showed comparable overall survival (OS) and first-line progression-free survival (PFS1) outcomes in the overall cohort of patients with metastatic BC (both P > .05), better OS (hazard ratio [HR] 0.76; P = .027) and PFS1 (HR 0.69; P = .001) in the TNBC subgroup, and worse PFS1 (HR 1.23; P = .024) in the HR+/HER2− BC subgroup.
Study details: Findings are from a retrospective cohort including 20,624 patients with newly diagnosed metastatic BC, of which 325 had gBRCAm, 1138 had gBRCA WT, and 19,161 had not tested for gBRCA.
Disclosures: This study was funded by an industrial consortium. Several authors declared receiving personal fees, grants, nonfinancial support, or travel support from several sources, including some of the companies in the consortium. Seventeen authors declared no conflicts of interest.
Source: Mailliez A et al. Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database. Int J Cancer. 2022 (Sep 26). Doi: 10.1002/ijc.34304